The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger, E Buchdunger, BJ Druker - Blood, 2005 - ashpublications.org
Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical
studies were promising but the results of clinical trials by far exceeded expectations …
studies were promising but the results of clinical trials by far exceeded expectations …
The biology of CML blast crisis
B Calabretta, D Perrotti - Blood, 2004 - ashpublications.org
Chronic myelogenous leukemia (CML) evolves from a chronic phase characterized by the
Philadelphia chromosome as the sole genetic abnormality into blast crisis, which is often …
Philadelphia chromosome as the sole genetic abnormality into blast crisis, which is often …
Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease
C Yoshida, JV Melo - International journal of hematology, 2004 - Springer
Chronic myeloid leukemia (CML) is a stem cell disorder caused by a constitutively activated
tyrosine kinase, the Bcr-Abl oncoprotein. An inhibitor of this tyrosine kinase, imatinib …
tyrosine kinase, the Bcr-Abl oncoprotein. An inhibitor of this tyrosine kinase, imatinib …